Fludrocortisone

Evidence Level: L5

Predicted Indications: 8

Fludrocortisone

Pharmacist Assessment Report

Fludrocortisone: From Mineralocorticoid Replacement to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Fludrocortisone is a synthetic corticosteroid with mainly mineralocorticoid activity. It is marketed in Canada, but the data compiled for this report do not list an approved indication. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma, but no clinical trials and no publications currently support this prediction, so it should be treated as a computational hypothesis only.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Primary cutaneous T-cell lymphoma
TxGNN Prediction Score	0.9958
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on general pharmacology, fludrocortisone is a mineralocorticoid with some glucocorticoid activity.

Systemic and topical corticosteroids have a role in managing cutaneous T-cell lymphoma, which is the only plausible link to this prediction. However, fludrocortisone is not an established agent for this disease. The very high TxGNN score is a computational output only. No trials or literature support it, and no specific mechanistic link could be identified from the available data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for primary cutaneous T-cell lymphoma.

For context, the other predicted indications also lack clinical trials. The only one with notable literature is “eye disease” (rank 6, evidence level L4, recommendation: Research Question). The most relevant items are:

PMID	Year	Type	Journal	Key Findings
36161841	2022	Phase 1B study	BMJ Open Ophthalmology	Safety and tolerability of single-dose intravitreal fludrocortisone acetate in geographic atrophy
34509498	2021	Preclinical	Experimental Eye Research	Anti-inflammatory and neuroprotective properties of fludrocortisone in retinal degeneration
11008895	1999	Clinical study	International Ophthalmology	Fludrocortisone for systemic hypotension in primary open-angle glaucoma patients

The remaining retrieved papers are mostly reviews and case reports on dysautonomia, Parkinson’s non-motor symptoms, autoimmune polyglandular syndromes and Sjögren’s-related renal tubular acidosis. They provide no direct support for an ocular indication.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02552248	JAMP FLUDROCORTISONE	Not specified	Not specified
02086026	FLORINEF	Not specified	Not specified

Safety Considerations

Drug Interactions: 446 interactions were identified. Examples of those listed:

Major: Bupropion
Moderate: antidiabetic agents (acarbose, pioglitazone, alogliptin, canagliflozin, dapagliflozin, empagliflozin, linagliptin, chlorpropamide, albiglutide, dulaglutide), amphotericin B, aprepitant, acetylsalicylic acid, clarithromycin, bisacodyl, picosulfuric acid, oxandrolone, oxymetholone

For warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for primary cutaneous T-cell lymphoma rests only on a model score, with no clinical trials, no literature and no supported mechanistic link. The other top predictions (cystic teratoma, dermoid cysts, exostosis and broad orbital categories) are similarly unsupported. The only signal worth following is a preclinical and early clinical one for retinal degeneration (geographic atrophy), which is a separate research question.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, which are currently missing and block safety screening
Mechanism of action data (for example from DrugBank)
Approved indication text for the two Canadian licences
For primary cutaneous T-cell lymphoma, preclinical or mechanistic evidence showing a rationale for fludrocortisone over established corticosteroids
If the ocular direction is pursued, a specific condition (for example geographic atrophy) instead of the broad “eye disease” category, and a route-of-administration assessment, since the early clinical study used intravitreal injection
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.